Quantum Surgical acquires NeuWave Medical for robotic cancer treatment

Quantum Surgical announced the acquisition of NeuWave Medical Inc. on February 27, 2026. The company specializes in minimally invasive robotic-assisted cancer treatment. It developed the Epione robotic platform for treating early-stage tumors through percutaneous ablations. Epione assists physicians in performing percutaneous tumor ablations. The device has received CE Mark approval for abdominal, chest, and musculoskeletal structures indications and is FDA cleared for the abdominal ablation indication in the United States. NeuWave Medical markets a microwave ablation technology for percutaneous ablations that is available in the United States at leading cancer centers. The acquisition supports the strategy to democratize robotic-assisted tumor ablation treatments to reduce cancer mortality. The two companies will operate as subsidiaries of Precision IO Group Inc., a newly created parent company led by medtech veteran Kurt Azarbarzin, who was recently appointed CEO. Both companies will continue to operate independently to ensure a smooth and uninterrupted experience for their users while their activities complement each other.